About iCDP Summit

Welcome to the 5th International Cannabinoid-Derived Pharmaceuticals Summit

The 5th International Cannabinoid-Derived Pharmaceuticals Summit brings together drug developers working on the complex production of both plant-based, biosynthetic and synthetic endocannabinoid system modulators. An elite faculty of speakers will present on crucial topics such as rigorous clinical trial data exchange, and guide discussion through vital non-clinical focus points such as IP and funding strategy – as well as cutting edge insights from the academic world. Meet face-to-face with decision-makers from the likes of Jazz Pharmaceuticals Greenwich BiosciencesACHEMCannvalate, Cannabics PharmaceuticalsOxford Cannabinoid Technologies and many more at the first physical cannabinoid conference of the year.

What’s new for 2022?

  • The lack of human evidence for the mechanism of action for cannabinoids major and minor in different therapeutic areas – led by Anthony Almada from Imaginutrition and other key stakeholders
  • The wealth of RWE that can be utilised in a way that could uncover further potential for cannabinoid therapeutics with Jeff Chen, Radicle
  • For the first time ever, an MP from UK government will discuss the ins and outs of drug reform in the UK and the current roadblocks


5 Reasons to Join Us This Year

icon 1
icon 2
icon 3
icon 4
icon 5

Our new two-stream agenda offers more content and greater depth than ever before with over 35+ speakers and two workshops on OTC cannabinoids and Psychedelics. It’s our most comprehensive agenda to date!

Refine your preclinical research process with case study-led presentations from two industry-leading specialists, Hunter Land (Alterola Biotech Inc.) & Melanie Kelly (Tetra Biopharma)


Get an update on where the best quality cannabinoids are coming from, including synthetic, biosynthetic and plant-based sources with Purisys, Aphios and Inmed

Design robust clinical trials at all phases by joining Cannvalate for an interactive session focused on phases 2 and 3

Find collaborators and partners that will enable you to take your research to the next level, with the largest audience of pharmaceutically-focused cannabinoid specialists